v3.25.2
Acquisition
6 Months Ended
Jun. 28, 2025
Business Combinations [Abstract]  
Acquisition

4. ACQUISITION

 

On April 1, 2025, the Company, Thrive Skilled Pediatric Care, LLC, a Delaware limited liability company (“Thrive”), and other parties thereto entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, following a series of mergers, Thrive would become a wholly-owned subsidiary of the Company (collectively, the "Merger"). Thrive is an independent provider of pediatric home care with 23 locations in seven states including Arizona, Georgia, Kansas, New Mexico, North Carolina, Virginia, and Texas. Thrive primarily provides skilled Private Duty Nursing services, but also provides Pediatric Therapy, Licensed Health Aide Services, and Certified Nurse Assistant Services.

 

On June 2, 2025, the Company paid approximately $75.7 million as consideration upon consummation of the Merger, including the issuance of 11.2 million shares of common stock, equating to $59.8 million based on the opening market price of the Company’s common stock on the closing date. This issuance of the shares of common stock did not involve a public offering and was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering.

 

The Merger Agreement provides for customary purchase price adjustments, and approximately 1.3 million shares of the Company’s common stock is being held in escrow for a period of up to 12 months following the closing to support obligations under the Merger Agreement.

 

The preliminary purchase price allocation as of the acquisition date, reflecting measurement period adjustments made during the respective period, are as follows (amounts in thousands):

 

Entity

Thrive

 

Acquisition Date

June 2, 2025

 

Cash consideration

$

15,855

 

Share-based consideration

 

59,838

 

Total

$

75,693

 

 

 

 

Cash and cash equivalents

$

1,002

 

Patient accounts receivable

 

20,050

 

Receivables under insured programs

 

306

 

Prepaid expenses

 

494

 

Other current assets

 

308

 

Property and equipment

 

131

 

Operating lease right of use assets

 

1,835

 

Intangible assets - licenses

 

5,000

 

Intangible assets - trade names

 

540

 

Receivables under insured programs - long term

 

1,439

 

Other long-term assets

 

1,095

 

 

 

 

Accounts payable and other accrued liabilities

 

1,754

 

Accrued payroll and employee benefits

 

4,322

 

Current portion of insurance reserves

 

679

 

Current portion of operating lease liabilities

 

741

 

Other current liabilities

 

9,935

 

Long-term insurance reserves

 

2,160

 

Operating lease liabilities, less current portion

 

1,094

 

 

 

 

Total identifiable net assets

 

11,515

 

Goodwill

 

64,178

 

Total

$

75,693

 

 

The purchase price allocation is preliminary pending a final analysis of the impact of income taxes and finalization of the fair value of intangible assets and net working capital. The preliminary goodwill recognized is attributable to the excess of the particular purchase price of the acquisition over the fair value of identifiable net assets acquired, including other identified intangible assets. Goodwill is primarily attributable to expected synergies resulting from the acquisition. Preliminary goodwill from the Merger was allocated to segments as follows (amounts in thousands):

 

 

PDS

 

 

HHH

 

 

MS

 

 

Total

 

Balance at December 28, 2024 and March 29, 2025, net (1)

$

897,728

 

 

$

46,188

 

 

$

110,636

 

 

$

1,054,552

 

Acquisition

 

64,178

 

 

 

-

 

 

 

-

 

 

 

64,178

 

Balance at June 28, 2025, net (1)

 

961,906

 

 

 

46,188

 

 

 

110,636

 

 

 

1,118,730

 

 

(1) Goodwill balance is net of accumulated impairment losses of $608.0 million for PDS, $119.8 million for MS, and $487.4 million for HHH.

 

The Company incurred transaction costs of $3.4 million and $3.5 million during the three and six-month periods ended June 28, 2025, respectively. No such cost was recognized during either the three or six-month period ended June 29, 2024. These costs are included in acquisition-related costs in the accompanying consolidated statement of operations.

 

Pro forma financial information related to the above acquisitions has not been provided as it is not material to the Company’s consolidated results of operations. The results of operations of the above acquisition are included in the Company’s consolidated results of operations from the date of acquisition and were not significant for the six-month period ended June 28, 2025.